Fujifilm has issued a press release stating that their antiviral drug, Avigan, is to enter Phase II clinical trials in the USA. As previously reported, Avigan caused Fujifilm’s shares to increase by 8.8% in February after Japanese health authorities announced their plans to recommend it for COVID-19 treatment. Their shares jumped 15% after successful trials of the drug in China.
Avigan, also available in other parts of the world under the name “Favipiravir”, has been approved in Japan as an influenza antiviral drug, but it’s also been effective in treating other viruses such as ebola. Now it seems to be somewhat effective against COVID-19, the illness caused by the SARS-CoV-2 coronavirus.